Immuron Bilan de santé

Santé financière contrôle des critères 6/6

Immuron possède un total de capitaux propres de A$12.7M et une dette totale de A$0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont A$15.5M et de A$2.8M.

Informations clés

Ratio d'endettement

AU$0

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	AU$11.66m
Fonds propres	AU$12.71m
Total du passif	AU$2.84m
Total des actifs	AU$15.55m

Mises à jour récentes de la santé financière

Pas de mise à jour

Recent updates

Immuron suspends research on COVID-19 program

Aug 19

Immuron says proposed trials of antibacterial drug put on clinical hold by FDA

Jul 26

Immuron to get European patent for drug composition to treat bacterial infection

Jul 07

Immuron inks SARS-CoV-2 research agreement with Monash University, shares +12%

Dec 15

Immuron soars 26% on positive vaccine responses in gut mediated pathogens

Nov 11

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de IMRN ( A$14.7M ) dépassent ses passifs à court terme ( A$2.7M ).

Passif à long terme: Les actifs à court terme de IMRN ( A$14.7M ) dépassent ses passifs à long terme ( A$141.5K ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: IMRN est sans dette.

Réduire la dette: IMRN n'avait aucune dette il y a 5 ans.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: IMRN dispose d'une piste de trésorerie suffisante pour plus d'un an sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: IMRN dispose d'une marge de trésorerie suffisante pour 1.5 ans si le flux de trésorerie disponible continue de diminuer à un taux historique de 9.9 % chaque année.

Immuron Bilan de santé

Santé financière contrôle des critères 6/6

Informations clés

Mises à jour récentes de la santé financière

Recent updates

Immuron Limited, Annual General Meeting, Nov 18, 2024

Immuron Limited Announces NMRC Reports Results for Campylobacter Clinical Study

Immuron Limited has filed a Follow-on Equity Offering in the amount of $2.069083 million.

Immuron Requests Pre-IND Meeting for IMM-529 with FDA Filing

Immuron Limited Appoints Jeannette Joughin as Director

Immuron Limited Announces Resignation of Roger Aston as Non-Executive Director

Immuron Limited Announces Positive Results Support Travelan Progress to Phase 3 Clinical Trials in the US

Immuron Limited Clinical Trials Update

Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study

Immuron Limited, Annual General Meeting, Nov 21, 2023

Immuron Limited Announces Travelan® Clinical Study Cohort 2 Commences

Immuron Limited Announces First Patients Enrolled in Travelan® Clinical Study

Immuron Limited Initiates Recruitment of Travelan Clinical Study

Immuron Limited Announces US Food and Drug Administration Removed Clinical Hold on New Campylobacter ETEC Therapeutic Paves Way for Clinical Trial Initiation

Immuron US DoD Naval Medical Research Center Responds to FDA Clinical Hold for New Campylobacter ETEC Therapeutic

Immuron Limited Receives FDA Approval for Travelan IND Application

Immuron Limited Submits IND Application To FDA for Travelan

Immuron Limited, Annual General Meeting, Oct 28, 2022

Immuron Limited Provides Update on IMM-124E SARS-CoV-2 Research

Immuron suspends research on COVID-19 program

Immuron Limited Provides Update on IND Application for Campylobacter ETEC Therapeutic

Immuron says proposed trials of antibacterial drug put on clinical hold by FDA

Immuron to get European patent for drug composition to treat bacterial infection

Immuron US DoD Naval Medical Research Center Submits IND Application for New Campylobacter ETEC Therapeutic

Immuron Limited Provides Update on the Planned Clinical Trial to Evaluate the Efficacy of Travelan and Two Third Party Non-Antibiotic Products in Travelers' Diarrhea

Immuron Limited Appoints Steven Lydeamore as Chief Executive Officer, effective June 27, 2022

Immuron Limited Announces Work on the Investigational New Drug Application to Evaluate the Efficacy of A Single Dose Regimen of Travelan

Immuron Limited Provides Monash University Research Update on SARS-CoV-2 Program

Immuron Limited Provides Update on Progress of the Anti-Viral Activity of IMM-124E

Immuron inks SARS-CoV-2 research agreement with Monash University, shares +12%

Immuron Limited Announces That the Naval Medical Research Center Has Completed the Characterisation of the Colostrum Harvested from Cows Immunized with the Experimental Vaccine Developed to Target Campylobacter and Enterotoxigenic E.Coli

Immuron soars 26% on positive vaccine responses in gut mediated pathogens

Immuron Limited Announces US DoD NMRC Reports Positive Response to Vaccine

Immuron Limited Provides Shareholders and the Market with an Update on the Planned Clinical Programs in Travelers’ Diarrhea

Immuron Limited has completed a Follow-on Equity Offering in the amount of $20.000025 million.

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines